Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy

Cancer Science

Volumn 97, Issue 6, 2006, Pages 546-553

  Szatmári, Tünde ^a   Lumniczky, Katalin ^a   Désaknai, Szilvia ^a   Trajcevski, Stéphane ^b   Hídvégi, Egon J ^a   Hamada, Hirofumi ^c   Sáfrány, Géza ^a  

^a National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^b SORBONNE UNIVERSITÉ   (France)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; K RAS PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CELL COUNT; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CODE; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; IMMUNOGENICITY; MOUSE; MOUSE STRAIN; NONHUMAN; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GLIOBLASTOMA; HISTOCOMPATIBILITY ANTIGENS; MICE; MUTATION; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-MYC; RADIATION TOLERANCE; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33744548728     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00208.x     Document Type: Article

References (53)

1. DeAngelis LM. Brain tumours. N Engl J Med 2001; 344: 114-23.
2. Glioma Meta-analysis Trialists Group. Chemotherapy in adult high-grade glioma: A systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-18.
3. Legler JM, Gloeckler Ries LA, Smith MA et al. Brain and other central nervous system cancers: Recent trends in incidence and mortality. J Natl Cancer Inst 1999; 91: 1382-90.
4. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res 1970; 30: 2394-400.
5. Weiner NE, Pyles RB, Chalk CL et al. A syngeneic mouse glioma model for study of glioblastoma therapy. J Neuropathol Exp Neurol 1999; 58: 54-60.
6. Akbasak A, Oldfield EH, Saris SC. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg 1991; 75: 922-9.
7. Désaknai S, Lumniczky K, Ésik O, Hamada H, Sáfrány G. Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. J Gene Med 2003; 5: 377-85.
8. Herrlinger U, Kramm CM, Johnston KM et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997; 4: 345-52.
9. Lumniczky K, Désaknai S, Mangel L et al. Local tumor irradiation augments the anti-tumor effect of cytokine producing autologous cancer cell vaccines in a murine glioma model. Cancer Gene Ther 2002; 9: 44-52.
10. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cellular Immunol 1997; 178: 101-7.
11. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997; 10: 1065-72.
12. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse. Gene Ther 1999; 6: 1626-33.
13. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J. IFN-β gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 2000; 47: 117-24.
14. Nakamura T, Sato K, Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002; 13: 613-26.
15. Solly SK, Trajcevski S, Frisen C et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10: 30-9.
16. Lumniczky K, Antal S, Unger E, Wunderlich L, Hídvégi EJ, Sáfrány G. Carcinogenic alterations in murine liver, lung and uterus tumors induced by in utero exposure to ionizing radiation. Mol Carcinogen 1998; 21: 100-10.
17. Koizumi N, Mizuguchi H, Hosono T et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim Biophys Acta 2001; 1568: 13-20.
18. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 1995; 36: 548-55.
19. San-Galli F, Vrignaud P, Robert J, Coindre JM, Cohadon F. Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats. J Neurooncol 1989; 7: 299-304.
20. Li Y, Owusu A, Lehnert S. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2004; 58: 519-27.
21. Rubenstein M, Shaw M, Mirochnik Y et al. In vivo establishment of T98G human glioblastoma. Meth Find Exp Clin Pharmacol 1999; 21: 391-3.
22. Ozawa T, Wang J, Hu LJ, Bollen AW, Lamborn KR, Deen DF. Growth of human glioblastomas as xenografts in the brains of athymic rats. In Vivo 2002; 16: 55-60.
23. Vince GH, Bendszus M, Schweitzer T et al. Spontaneous regression of experimental gliomas: An immunohistochemical and MRI study of the C6 glioma spheroid implantation model. Exp Neurol 2004; 190: 478-85.
24. Acevedo-Duncan M, Peariman J, Zachariah B. Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin. C Cell Prolif 2001; 34: 31-41.
25. Yount GL, Levine KS, Kuriyama H, Haas-Kogan DA, Israel MA. Fas (APO-1/ CD95) signaling pathway is intact in radioresistant human glioma cells. Cancer Res 1999; 59: 1362-5.
26. Weizsacker M, Nagamune A, Winkelstroter R, Vieten H, Wechsler W. Radiation and drug response of the rat glioma RG2. Eur J Cancer Clin Oncol 1982; 18: 891-5.
27. Zhang W, Yamada H, Sakai N, Nozawa Y. Sensitization of C6 glioma cells to radiation by stauroporine, a potent protein kinase C inhibitor. J Neurooncol 1993; 15: 1-7.
28. Taghian A, Ramsay J, Allalunis-Turner J et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1993; 25: 243-9.
29. Taghian A, Dubois W, Budach W, Baumann M, Freeman J, Suit H. In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1995; 32: 99-104.
30. Abdel-Wahab Z, Dar MM, Hester D et al. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol 1996; 171: 246-54.
31. Sampson JH, Ashley DM, Archer GE et al. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 1997; 41: 1365-73.
32. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-7.
33. Ishii N, Tada M, Hamou MF et al. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 1999; 18: 5870-80.
34. Blaszczyk-Thurin MOI, Ertl HCJ. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scand J Immunol 2002; 56: 361-75.
35. Friend S. p53: A glimpse at the puppet behind the shadow play. Nature 1994; 265: 334-5.
36. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-9.
37. Trent J, Meltzer P, Rosenblum M et al. Evidence for rearrangement, amplification and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci USA 1986; 83: 470-3.
38. Shindo H, Tani E, Matsumuto T, Hashimoto T, Furuyama J. Stabilization of c-myc protein in human glioma cells. Acta Neuropathol (Berlin) 1993; 86: 345-52.
39. Zagzag D, Salnikow K, Chiriboga L et al. Downregulation of major histocompatibility antigens in invading glioma cells: Stealth invasion of the brain. Lab Invest 2005; 85: 328-41.
40. Oshiro S, Liu Y, Fukushima T, Asotra K, Black KL. Modified immunoregulation associated with interferon-gamma treatment of rat glioma. Neurol Res 2001; 23: 359-66.
41. Wen PY, Lampson MA, Lampson LA. Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: Implications for strategies of immunotherapy. J Neuroimmunol 1992; 36: 57-68.
42. Anderson RC, Elder JB, Brown MD et al. Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol 2002; 102: 84-95.
43. Oshiro S, Fukushima T, Tomonaga M, Black KL. Response of MHC class-1 antigen on rat glioma cells to cytokines. Anticancer Res 2000; 20: 605-10.
44. Wen P, Loeffler JS, Morris JH, Lampson LA. The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol 1990; 27: 239-44.
45. Parney IF, Farr-Jones MA, Chang LJ, Petruk KC. Human glioma immunobiology in vitro: Implications for immunogene therapy. Neurosurgery 2000; 46: 1169-77.
46. Blume MR, Wilson CB, Vasquez DA. 1974; Immune response to a transplantable intracerebral glioma in rats. In: Sane K, Ishi S, LeVray D, eds. Recent Progress in Neurologic Surgery. Amsterdam: Excerpta Medica, 1974; 129-34.
47. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94-7.
48. Watts RG, Merchant RE. Cerebrovascular effects and tumor kinetics after a single intratumoral injection of human recombinant interleukin-2 alone or in combination with intravenous chemotherapy in a rat model of glioma. Neurosurgery 1992; 31: 89-99.
49. Tzeng JJ, Barth RF, Orosz GC, James SM. Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and non-immunogenic rat brain tumors. Cancer Res 1991; 51: 2373-8.
50. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9L gliosarcoma. J Neurooncol 1994; 22: 191-200.
51. Tzeng JJ, Barth RF, Clendenon NR, Gordon WA. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 1990; 50: 4338-43.
52. Smilowitz HM, Joel DD, Slatkin DN et al. Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS. J Neurooncol 2000; 46: 193-203.
53. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003; 63: 8487-91.